Cargando…

Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting

Transrectal ultrasound (TRUS) biopsy can miss 20–30% of clinically significant cancers. We evaluate an alternative approach—transperineal template-guided mapping biopsy (TTMB) in the initial and repeat biopsy setting. From January 2005 through September 2008, 373 consecutive men underwent TTMB (294...

Descripción completa

Detalles Bibliográficos
Autores principales: Taira, A V, Merrick, G S, Galbreath, R W, Andreini, H, Taubenslag, W, Curtis, R, Butler, W M, Adamovich, E, Wallner, K E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834351/
https://www.ncbi.nlm.nih.gov/pubmed/19786982
http://dx.doi.org/10.1038/pcan.2009.42
_version_ 1782178563303145472
author Taira, A V
Merrick, G S
Galbreath, R W
Andreini, H
Taubenslag, W
Curtis, R
Butler, W M
Adamovich, E
Wallner, K E
author_facet Taira, A V
Merrick, G S
Galbreath, R W
Andreini, H
Taubenslag, W
Curtis, R
Butler, W M
Adamovich, E
Wallner, K E
author_sort Taira, A V
collection PubMed
description Transrectal ultrasound (TRUS) biopsy can miss 20–30% of clinically significant cancers. We evaluate an alternative approach—transperineal template-guided mapping biopsy (TTMB) in the initial and repeat biopsy setting. From January 2005 through September 2008, 373 consecutive men underwent TTMB (294 men with ⩾1 prior negative biopsy and 79 men as the initial biopsy). The location of each positive biopsy core, number of positive cores, and percent involvement of each core was recorded. Cancer detection rate for the initial biopsy was 75.9%. For men with 1, 2, and ⩾3 prior negative biopsies detection rates were 55.5%, 41.7%, and 34.4%, respectively. In all, 55.5% of the cancers identified were Gleason ⩾7. The majority of the cancers were multifocal. There was no significant change in the number of positive cores or Gleason score as the number of prior biopsies increased. The anterior and apical aspects of the prostate were among the most common cancer locations. TTMB provides a high rate of cancer detection as initial and repeat biopsy. TTMB was particularly effective at diagnosing anterior and apical cancer. TTMB may have particular application for men considering active surveillance, with prior negative TRUS biopsies, and those considering subtotal gland or other minimally invasive treatments.
format Text
id pubmed-2834351
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28343512010-03-29 Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting Taira, A V Merrick, G S Galbreath, R W Andreini, H Taubenslag, W Curtis, R Butler, W M Adamovich, E Wallner, K E Prostate Cancer Prostatic Dis Original Articles Transrectal ultrasound (TRUS) biopsy can miss 20–30% of clinically significant cancers. We evaluate an alternative approach—transperineal template-guided mapping biopsy (TTMB) in the initial and repeat biopsy setting. From January 2005 through September 2008, 373 consecutive men underwent TTMB (294 men with ⩾1 prior negative biopsy and 79 men as the initial biopsy). The location of each positive biopsy core, number of positive cores, and percent involvement of each core was recorded. Cancer detection rate for the initial biopsy was 75.9%. For men with 1, 2, and ⩾3 prior negative biopsies detection rates were 55.5%, 41.7%, and 34.4%, respectively. In all, 55.5% of the cancers identified were Gleason ⩾7. The majority of the cancers were multifocal. There was no significant change in the number of positive cores or Gleason score as the number of prior biopsies increased. The anterior and apical aspects of the prostate were among the most common cancer locations. TTMB provides a high rate of cancer detection as initial and repeat biopsy. TTMB was particularly effective at diagnosing anterior and apical cancer. TTMB may have particular application for men considering active surveillance, with prior negative TRUS biopsies, and those considering subtotal gland or other minimally invasive treatments. Nature Publishing Group 2009-09-29 2010-03 /pmc/articles/PMC2834351/ /pubmed/19786982 http://dx.doi.org/10.1038/pcan.2009.42 Text en Copyright 2010, Nature Publishing Group http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Articles
Taira, A V
Merrick, G S
Galbreath, R W
Andreini, H
Taubenslag, W
Curtis, R
Butler, W M
Adamovich, E
Wallner, K E
Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
title Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
title_full Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
title_fullStr Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
title_full_unstemmed Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
title_short Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
title_sort performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834351/
https://www.ncbi.nlm.nih.gov/pubmed/19786982
http://dx.doi.org/10.1038/pcan.2009.42
work_keys_str_mv AT tairaav performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting
AT merrickgs performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting
AT galbreathrw performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting
AT andreinih performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting
AT taubenslagw performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting
AT curtisr performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting
AT butlerwm performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting
AT adamoviche performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting
AT wallnerke performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting